2. Academic Validation
  3. mTORC signaling in hematopoiesis

mTORC signaling in hematopoiesis

  • Int J Hematol. 2016 May;103(5):510-8. doi: 10.1007/s12185-016-1944-z.
Xiaomin Wang 1,  Yajing Chu 1,  Weili Wang 1,  Weiping Yuan 2
Affiliations

Affiliations

  • 1 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China.
  • 2 State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, and Center for Stem Cell Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300020, China. wpyuan@ihcams.ac.cn.
PMID: 26791377 DOI: 10.1007/s12185-016-1944-z
Abstract

mTOR is a serine/threonine (Ser/Thr) protein kinase that responds to multiple signals, including growth factors, Amino acids, energy status, stress, and oxygen, regulates cell survival, cell growth, the cell cycle, and cell metabolism, and maintains homeostasis [1]. Increased or decreased mTORC1 activity can alter HSC function and cause hematological disorders [2, 3]. Therefore, a comprehensive knowledge of mTOR is critical to understanding how HSCs function and maintain homeostasis in the hematopoietic system. In this review, we summarize recent advances in the understanding of the mTOR signaling pathway and its roles in hematopoiesis and leukemia. We also discuss pharmacological approaches to manipulate mTOR activity.

Keywords

HSC; Hematopoiesis; Leukemia; Leukemogenesis; Targeted therapy; mTOR.

Figures
Products